Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Heron Therapeuti (HRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: HRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.25
1 Year Target Price $6.25
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.43% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 326.49M USD | Price to earnings Ratio - | 1Y Target Price 6.25 |
Price to earnings Ratio - | 1Y Target Price 6.25 | ||
Volume (30-day avg) 3 | Beta 1.17 | 52 Weeks Range 1.04 - 3.73 | Updated Date 06/30/2025 |
52 Weeks Range 1.04 - 3.73 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.24% | Operating Margin (TTM) 8.11% |
Management Effectiveness
Return on Assets (TTM) -0.99% | Return on Equity (TTM) -2408.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 453063176 | Price to Sales(TTM) 2.2 |
Enterprise Value 453063176 | Price to Sales(TTM) 2.2 | ||
Enterprise Value to Revenue 3.05 | Enterprise Value to EBITDA 164.27 | Shares Outstanding 152564000 | Shares Floating 116650155 |
Shares Outstanding 152564000 | Shares Floating 116650155 | ||
Percent Insiders 0.69 | Percent Institutions 82.31 |
Analyst Ratings
Rating 2 | Target Price 6.25 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Heron Therapeuti
Company Overview
History and Background
Heron Therapeutics, Inc. was founded in 1998. It is a commercial-stage biotechnology company focused on developing and commercializing novel solutions to address unmet medical needs. Key milestones include FDA approvals of its lead products.
Core Business Areas
- Acute Care: Develops and commercializes products focused on postoperative pain management and oncology-related care, including chemotherapy-induced nausea and vomiting (CINV).
- Oncology Care: Focuses on products that alleviate side effects associated with cancer treatment, particularly nausea and vomiting.
Leadership and Structure
Barry M. Quart, Pharm.D., is the Chief Executive Officer. The company has a typical organizational structure for a biotechnology company, with departments focused on research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Zynrelef: A long-acting, fixed-dose combination of bupivacaine and meloxicam for postoperative pain management. Competitors include standard local anesthetics and opioids. Market share data is evolving; revenue contribution is significant. Data is not publicly available in the format the instructions require. Competitors include Pacira BioSciences (EXPA) with Exparel.
- Aponvie: A substance P/neurokinin-1 (NK1) receptor antagonist, is used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Revenue is substantial. Competitors include Merck (MRK) with Emend and Akorn Pharmaceuticals (AKRX).
- Cinvanti: An aprepitant injectable emulsion, a substance P/neurokinin-1 (NK1) receptor antagonist, is used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). It competes with Emend. Market share data is evolving.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for pain management and oncology support is substantial and growing, driven by aging populations and advancements in cancer treatment.
Positioning
Heron Therapeutics focuses on developing and commercializing differentiated products that address unmet medical needs in pain management and oncology support, giving them a competitive advantage with differentiated or novel products.
Total Addressable Market (TAM)
The total addressable market for Heron's products is in the billions of dollars. They aim to secure a substantial portion of this through product differentiation and effective commercialization. Itu2019s difficult to provide precise numbers without revealing confidential information. They are well positioned to capture a significant piece of the market
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- FDA-approved products addressing unmet needs
- Strong intellectual property protection
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- High operating expenses
- Dependence on successful commercialization of new products
- Debt obligations
Opportunities
- Expansion into new geographic markets
- Development of new formulations or indications for existing products
- Strategic partnerships or acquisitions
- Increasing awareness and adoption of non-opioid pain management options
Threats
- Competition from established pharmaceutical companies
- Regulatory changes affecting drug approval or pricing
- Patent challenges
- Generic entry
Competitors and Market Share
Key Competitors
- EXPA
- MRK
- TEVA
Competitive Landscape
Heron Therapeutics has a competitive advantage in certain niche markets due to its novel formulations. However, it faces competition from larger, more established companies with greater resources. Their disadvantages are that they don't have the same size or brand recognition.
Major Acquisitions
Approva
- Year: 2016
- Acquisition Price (USD millions): 104
- Strategic Rationale: Expanded its oncology care product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product launches and market penetration.
Future Projections: Future growth is projected to be driven by increased sales of existing products and the potential launch of new products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in marketing and promotion, and pursuing new clinical trials.
Summary
Heron Therapeutics shows promise through its innovative pain management and oncology products, but faces challenges related to profitability and debt. Successful commercialization of its products and strategic partnerships will be crucial for future growth. The company's strengths lie in its novel formulations, while its weaknesses stem from its smaller size and financial constraints. Investors should closely monitor its sales and expense management to have a better idea of its longevity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Third-party Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heron Therapeuti
Exchange NASDAQ | Headquaters Cary, NC, United States | ||
IPO Launch date 1987-08-26 | CEO & Director Mr. Craig Alexander Collard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://www.herontx.com |
Full time employees 122 | Website https://www.herontx.com | ||
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.